The phase 3 IMforte trial(NCT05091567) demonstrated benefit for expanding on maintenance immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) by adding the chemotherapy lurbinectedin (Zepzelca). During a live Community Case Forum…
Addition of Lurbinectedin Improves Duration of Maintenance in ES-SCLC | Targeted Oncology
